{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T08:56:51Z","timestamp":1764320211925,"version":"3.46.0"},"reference-count":27,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background: Carbapenem-resistant Enterobacterales and difficult-to-treat resistance (DTR) Pseudomonas aeruginosa are a growing public health issue. Cefiderocol demonstrated activity against \u03b2-lactamase-producing Gram-negative bacteria (GNB). However, bone PharmacoKinetics (PK) data is lacking. Here, we report a case of post-traumatic chronic osteomyelitis caused by extensively drug-resistant (XDR) Pseudomonas aeruginosa which was successfully treated with cefiderocol. Moreover, we conducted a non-systematic review of the available literature. Case Report: We described the case of a 64-year-old man who was admitted to a traumatology ward after a work accident caused crushing of his left foot. Microbiological tests on intraoperative biopsies demonstrated XDR P. aeruginosa and K. oxytoca. Despite the administrations of different antibiotics regimens and multiple surgical revisions, the patient developed chronic osteomyelitis. To prevent amputation, cefiderocol was prescribed for six weeks, resulting in a complete clinical resolution of osteomyelitis. Review of the Literature: We performed a non-systematic review of the literature searching the public databases PubMed and Google Scholar. We identified nine case reports. In most patients (60%) the cause of osteomyelitis was post-surgical, and all the reported cases were healthcare associated. Osteomyelitis treatment required both antimicrobial therapy and surgery in all the cases described. Cefiderocol was often prescribed in association with other antibiotics (70%). Clinical cure was described in all the reported cases. Conclusions: This study highlights that cefiderocol is safe and efficacious to treat osteomyelitis caused by carbapenem-resistant GNB. However, evidence is limited to a few case reports.<\/jats:p>","DOI":"10.3390\/antibiotics14121199","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T08:26:57Z","timestamp":1764318417000},"page":"1199","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cefiderocol as a Successful Therapy for Osteomyelitis Due to XDR Pseudomonas aeruginosa: A Case Report and Literature Review"],"prefix":"10.3390","volume":"14","author":[{"given":"Alice","family":"Mul\u00e8","sequence":"first","affiliation":[{"name":"Division of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Cambianica","sequence":"additional","affiliation":[{"name":"Division of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Matteelli","sequence":"additional","affiliation":[{"name":"Division of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Lorenzotti","sequence":"additional","affiliation":[{"name":"Division of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7861-4758","authenticated-orcid":false,"given":"Angelica","family":"Lenzi","sequence":"additional","affiliation":[{"name":"Division of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3807-7766","authenticated-orcid":false,"given":"Francesco","family":"Rossini","sequence":"additional","affiliation":[{"name":"Division of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessio","family":"Sollima","sequence":"additional","affiliation":[{"name":"Division of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"Capone","sequence":"additional","affiliation":[{"name":"Unit of Prison Health, ASST Papa Giovanni XXIII, 24127 Bergamo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9161-7804","authenticated-orcid":false,"given":"Francesco","family":"Castelli","sequence":"additional","affiliation":[{"name":"Division of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S521","DOI":"10.1093\/cid\/ciz824","article-title":"Epidemiology and Diagnostics of Carbapenem Resistance in Gram-Negative Bacteria","volume":"69","author":"Nordmann","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e00093-17","DOI":"10.1128\/AAC.00093-17","article-title":"In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study)","volume":"61","author":"Hackel","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijantimicag.2018.10.007","article-title":"In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, against a Recent Collection of Clinically Relevant Carbapenem-Non-Susceptible Gram-Negative Bacilli, Including Serine Carbapenemase- and Metallo-\u03b2-Lactamase-Producing Isolates (SIDERO-WT-2014 Study)","volume":"53","author":"Kazmierczak","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40265-019-1055-2","article-title":"Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli","volume":"79","author":"Zhanel","year":"2019","journal-title":"Drugs"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/jac\/dky425","article-title":"In Vitro Activities of Cefiderocol, Ceftolozane\/Tazobactam, Ceftazidime\/Avibactam and Other Comparative Drugs against Imipenem-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, All Associated with Bloodstream Infections in Taiwan","volume":"74","author":"Hsueh","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and Safety of Cefiderocol or Best Available Therapy for the Treatment of Serious Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria (CREDIBLE-CR): A Randomised, Open-Label, Multicentre, Pathogen-Focused, Descriptive, Phase 3 Trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Den Cefiderocol versus Imipenem-Cilastatin for the Treatment of Complicated Urinary Tract Infections Caused by Gram-Negative Uropathogens: A Phase 2, Randomised, Double-Blind, Non-Inferiority Trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus High-Dose, Extended-Infusion Meropenem for the Treatment of Gram-Negative Nosocomial Pneumonia (APEKS-NP): A Randomised, Double-Blind, Phase 3, Non-Inferiority Trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s13300-022-01357-2","article-title":"The Role of Novel Antibiotics in the Management of Diabetic Foot Infection","volume":"14","author":"Mougakou","year":"2023","journal-title":"Diabetes Ther."},{"key":"ref_10","unstructured":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators (2018). Global, Regional, and National Incidence, Prevalence, and Years Lived with Disability for 354 Diseases and Injuries for 195 Countries and Territories, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017. Lancet, 392, 1789\u20131858."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"106763","DOI":"10.1016\/j.ijantimicag.2023.106763","article-title":"Off-Label Use versus Formal Recommendations of Conventional and Novel Antibiotics for the Treatment of Infections Caused by Multidrug-Resistant Bacteria","volume":"61","author":"Jean","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/jbcr\/irae026","article-title":"Bone and Skin\/Subcutaneous Tissue Concentrations of Cefiderocol During Treatment of Extensively Drug-Resistant Pseudomonas aeruginosa","volume":"45","author":"Mueller","year":"2024","journal-title":"J. Burn Care Res."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Alamarat, Z.I., Babic, J., Tran, T.T., Wootton, S.H., Dinh, A.Q., Miller, W.R., Hanson, B., Wanger, A., Gary, J.L., and Arias, C.A. (2020). Long-Term Compassionate Use of Cefiderocol To Treat Chronic Osteomyelitis Caused by Extensively Drug-Resistant Pseudomonas aeruginosa and Extended-Spectrum-\u03b2-Lactamase-Producing Klebsiella pneumoniae in a Pediatric Patient. Antimicrob. Agents. Chemother., 64.","DOI":"10.1128\/AAC.01872-19"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1080\/23744235.2020.1856921","article-title":"Recurrent Neurosurgical Site Infection by Extensively Drug-Resistant P. aeruginosa Treated with Cefiderocol: A Case Report and Literature Review","volume":"53","author":"Bavaro","year":"2021","journal-title":"Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"i18","DOI":"10.1093\/jacamr\/dlab054","article-title":"Education: A Compassionate Use of Cefiderocol to Treat Osteomyelitis Caused by an XDR Pseudomonas aeruginosa","volume":"3","author":"Chavda","year":"2021","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1038\/s41467-022-31837-9","article-title":"Personalized Bacteriophage Therapy to Treat Pandrug-Resistant Spinal Pseudomonas aeruginosa Infection","volume":"13","author":"Ferry","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/phar.2660","article-title":"Successful Prolonged Treatment of a Carbapenem-Resistant Acinetobacter baumannii Hip Infection with Cefiderocol: A Case Report","volume":"42","author":"Rose","year":"2022","journal-title":"Pharmacotherapy"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"dlac046","DOI":"10.1093\/jacamr\/dlac046","article-title":"Combination of Phage Therapy and Cefiderocol to Successfully Treat Pseudomonas aeruginosa Cranial Osteomyelitis","volume":"4","author":"Simner","year":"2022","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e258207","DOI":"10.1136\/bcr-2023-258207","article-title":"Cefiderocol-Associated Brown Chromaturia","volume":"16","author":"Smith","year":"2023","journal-title":"BMJ Case Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"ofaa185","DOI":"10.1093\/ofid\/ofaa185","article-title":"Cefiderocol for Extensively Drug-Resistant Gram-Negative Bacterial Infections: Real-World Experience From a Case Series and Review of the Literature","volume":"7","author":"Zingg","year":"2020","journal-title":"Open Forum. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Karakonstantis, S., Rousaki, M., and Kritsotakis, E.I. (2022). Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance. Antibiotics, 11.","DOI":"10.3390\/antibiotics11060723"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Tamma, P.D., Heil, E.L., Justo, J.A., Mathers, A.J., Satlin, M.J., and Bonomo, R.A. (2024). Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin. Infect. Dis., ciae403.","DOI":"10.1093\/cid\/ciae403"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1093\/cid\/civ482","article-title":"2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adults","volume":"61","author":"Berbari","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.bjid.2013.12.005","article-title":"Diretrizes Panamericanas para el Tratamiento de las Osteomielitis e Infecciones de Tejidos Blandos Group Recommendations for the Treatment of Osteomyelitis","volume":"18","author":"Lima","year":"2014","journal-title":"Braz. J. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.cmi.2022.12.012","article-title":"ESCMID\/EUCIC Clinical Practice Guidelines on Perioperative Antibiotic Prophylaxis in Patients Colonized by Multidrug-Resistant Gram-Negative Bacteria before Surgery","volume":"29","author":"Righi","year":"2023","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e37018","DOI":"10.1097\/MD.0000000000037018","article-title":"Prevention and Control of Hospital-Acquired Infections with Multidrug-Resistant Organism: A Review","volume":"103","author":"Ji","year":"2024","journal-title":"Medicine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/1469-0691.12427","article-title":"ESCMID Guidelines for the Management of the Infection Control Measures to Reduce Transmission of Multidrug-Resistant Gram-Negative Bacteria in Hospitalized Patients","volume":"20","author":"Tacconelli","year":"2014","journal-title":"Clin. Microbiol. Infect."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/12\/1199\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T08:52:58Z","timestamp":1764319978000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/12\/1199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":27,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["antibiotics14121199"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics14121199","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]}}}